DRD2 and schizophrenia: Thus, TAAR1 has become a promising target for pharmacotherapy, and recent clinical trials suggest a potential use for schizophrenia of TAAR1 agonists with a new mechanism of action not involving blockade of D2 dopamine receptors [15].